Literature DB >> 29224471

Clinical relevance of liver histopathology and different histological classifications of NASH in adults.

Fabio Nascimbeni1,2, Stefano Ballestri3, Mariana Verdelho Machado4, Alessandro Mantovani5, Helena Cortez-Pinto4, Giovanni Targher5, Amedeo Lonardo1.   

Abstract

INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) encompasses simple steatosis and steatohepatitis (NASH) with or without fibrosis/cirrhosis and hepatocellular carcinoma. NAFLD occurs epidemically in most areas of the world, contributes to cardiovascular events and liver-related mortality and therefore exacts a major economic toll. Areas covered: Here we summarize what clinicians should know about NAFLD histopathology in adults. We report on the individual histological features and scoring systems of NAFLD: the NAFLD activity score (NAS) introduced by the NASH-Clinical Research Network, the 'Fatty Liver Inhibition of Progression' algorithm and Steatosis, Activity, and Fibrosis (SAF) score. Pros and cons of histological classifications in NASH are discussed. Special emphasis is given to liver histopathology in some high-risk patient groups, such as those with severe obesity and type 2 diabetes. Moreover, we also examine the relationship between liver histopathology and clinical features, and the impact of liver histopathology on the long-term prognosis of NAFLD. Finally, we propose an integrated diagnostic approach which utilizes both non-invasive tools and liver biopsy in those individual patients with suspected NAFLD. Expert commentary: Based on expert opinions, we conclude with a research agenda on NAFLD which focuses on the most burning topics to be addressed over the next five years.

Entities:  

Keywords:  Biomarkers; cirrhosis; fibrosis; hepatocellular carcinoma; liver histology; non-invasive diagnostic techniques; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; scoring systems; steatosis

Mesh:

Year:  2017        PMID: 29224471     DOI: 10.1080/17474124.2018.1415756

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  16 in total

Review 1.  Histological assessment based on liver biopsy: the value and challenges in NASH drug development.

Authors:  Xiao-Fei Tong; Qian-Yi Wang; Xin-Yan Zhao; Ya-Meng Sun; Xiao-Ning Wu; Li-Ling Yang; Zheng-Zhao Lu; Xiao-Juan Ou; Ji-Dong Jia; Hong You
Journal:  Acta Pharmacol Sin       Date:  2022-02-14       Impact factor: 7.169

2.  Collagen deposition in the liver is strongly and positively associated with T1rho elongation while fat deposition is associated with T1rho shortening: an experimental study of methionine and choline-deficient (MCD) diet rat model.

Authors:  Feng Zhao; Nan Zhou; Ji-Li Wang; Hua Zhou; Li-Qiu Zou; Wei-Xiang Zhong; Jian He; Cun-Jing Zheng; Sen-Xiang Yan; Yì Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2020-12

3.  Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal.

Authors:  Bashu Dev Pardhe; Shreena Shakya; Anjeela Bhetwal; Jennifer Mathias; Puspa Raj Khanal; Roshan Pandit; Jyotsna Shakya; Hari Om Joshi; Sujan Babu Marahatta
Journal:  BMC Gastroenterol       Date:  2018-07-06       Impact factor: 3.067

4.  Male-specific association between subclinical hypothyroidism and the risk of non-alcoholic fatty liver disease estimated by hepatic steatosis index: Korea National Health and Nutrition Examination Survey 2013 to 2015.

Authors:  Jeongmin Lee; Jeonghoon Ha; Kwanhoon Jo; Dong-Jun Lim; Jung-Min Lee; Sang-Ah Chang; Moo-Il Kang; Bong-Yun Cha; Min-Hee Kim
Journal:  Sci Rep       Date:  2018-10-11       Impact factor: 4.379

5.  Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study.

Authors:  Yoosoo Chang; Yoo-Hun Noh; Byung-Seong Suh; Yejin Kim; Eunju Sung; Hyun-Suk Jung; Chan-Won Kim; Min-Jung Kwon; Kyung Eun Yun; Jin-Won Noh; Hocheol Shin; Yong Kyun Cho; Seungho Ryu
Journal:  J Clin Med       Date:  2018-11-21       Impact factor: 4.241

6.  High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype.

Authors:  Nicole Golob-Schwarzl; Kira Bettermann; Anita Kuldeep Mehta; Sonja M Kessler; Julia Unterluggauer; Stefanie Krassnig; Kensuke Kojima; Xintong Chen; Yujin Hoshida; Nabeel M Bardeesy; Heimo Müller; Vendula Svendova; Michael G Schimek; Clemens Diwoky; Alexandra Lipfert; Vineet Mahajan; Cornelia Stumptner; Andrea Thüringer; Leopold F Fröhlich; Tatjana Stojakovic; K P R Nilsson; Thomas Kolbe; Thomas Rülicke; Thomas M Magin; Pavel Strnad; Alexandra K Kiemer; Richard Moriggl; Johannes Haybaeck
Journal:  Transl Oncol       Date:  2018-11-12       Impact factor: 4.243

7.  Association between Sleep Disturbances and Liver Status in Obese Subjects with Nonalcoholic Fatty Liver Disease: A Comparison with Healthy Controls.

Authors:  Bertha Araceli Marin-Alejandre; Itziar Abete; Irene Cantero; Jose I Riezu-Boj; Fermín I Milagro; J Ignacio Monreal; Mariana Elorz; José Ignacio Herrero; Alberto Benito-Boillos; Jorge Quiroga; Ana Martinez-Echeverria; Juan Isidro Uriz-Otano; María Pilar Huarte-Muniesa; Josep A Tur; J Alfredo Martínez; M Angeles Zulet
Journal:  Nutrients       Date:  2019-02-02       Impact factor: 5.717

8.  Insulin resistance associates with hepatic lobular inflammation in subjects with obesity.

Authors:  Frederique Van de Velde; Marlies Bekaert; Anja Geerts; Anne Hoorens; Arsène-Hélène Batens; Samyah Shadid; Margriet Ouwens; Yves Van Nieuwenhove; Bruno Lapauw
Journal:  Endocr Connect       Date:  2019-09       Impact factor: 3.335

9.  Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome.

Authors:  Hande Erman; Engin Beydogan; Seher Irem Cetin; Banu Boyuk
Journal:  Mediators Inflamm       Date:  2020-04-01       Impact factor: 4.711

10.  Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome.

Authors:  Semanti Chakraborty; Mohd Ashraf Ganie; Ibrahim Masoodi; Manisha Jana; Nandita Gupta; Nighat Yaseen Sofi
Journal:  Indian J Med Res       Date:  2020-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.